Interomex BioPharmaceuticals
Vancouver
About Interomex BioPharmaceuticals
Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease. The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $4.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2001)
- Website: interomex.com
Industries & Categories
Biopharma, Biotechnology, Medical
Canonical: https://fsome.com/organization/interomex-biopharmaceuticals-3381821 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.